Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Altretamine and Etoposide in Treating Patients With HIV-Related Cancer

Phase 1

Completed

Conditions: Lymphoma
Sarcoma

First Posted Date: 2004-05-13

Last Posted Date: 2013-02-04

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT00002936

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

First Posted Date: 2004-05-12

Last Posted Date: 2013-12-19

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 500

Registration Number: NCT00002802

Locations: 🇩🇪
University of Cologne, Frechen, Germany

High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2004-05-11

Last Posted Date: 2010-09-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00002788

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma

Phase 3

Conditions: Sarcoma

First Posted Date: 2004-05-05

Last Posted Date: 2013-09-17

Lead Sponsor: University Hospital Muenster

Registration Number: NCT00002516

Locations: 🇬🇧
Royal Victoria Infirmary, Newcastle-upon-Tyne, England, United Kingdom

Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma

Phase 2

Withdrawn

Conditions: Lymphoma

First Posted Date: 2004-05-04

Last Posted Date: 2021-10-27

Lead Sponsor: Medstar Health Research Institute

Registration Number: NCT00006669

Locations: 🇺🇸
Washington Cancer Institute, Washington, District of Columbia, United States
🇺🇸
Franklin Square Hospital Center, Baltimore, Maryland, United States

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer

First Posted Date: 2004-05-03

Last Posted Date: 2012-09-26

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 3

Registration Number: NCT00005612

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer

Phase 2

Conditions: Radiation Toxicity
Drug/Agent Toxicity by Tissue/Organ
Lung Cancer

First Posted Date: 2004-04-30

Last Posted Date: 2013-12-04

Lead Sponsor: University of Florida

Target Recruit Count: 20

Registration Number: NCT00003583

Locations: 🇺🇸
University of Florida - Gainesville, Gainesville, Florida, United States

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-04-30

Last Posted Date: 2019-11-04

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 25

Registration Number: NCT00003397

Locations: 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Conditions: Lymphoma

First Posted Date: 2004-04-29

Last Posted Date: 2013-12-18

Lead Sponsor: St. Luke's Medical Center

Registration Number: NCT00002481

Locations: 🇺🇸
St. Luke's Medical Center, Milwaukee, Wisconsin, United States

Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Leukemia
Neutropenia

First Posted Date: 2004-04-29

Last Posted Date: 2012-07-02

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 500

Registration Number: NCT00002719

Locations: 🇮🇹
Azienda Policlinico Umberto Primo, Rome, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy